GlassScriptPhysician profile
Claire Mcdonough
NPI 1023442142
$3,649.70
in general payments reported to CMS, 2019-2025
22 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $124 · 2023: $1,222 · 2024: $789 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.13 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.36 | 2021-2025 | Caplyta |
| Lundbeck LLC | $314.27 | 2021-2025 | Rexulti |
| Alkermes, INC. | $289.20 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $273.38 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $212.90 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $172.75 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $157.98 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $153.49 | 2021-2025 | Fanapt |
| Bausch Health US, LLC | $136.43 | 2024-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $113.51 | 2022-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $110.57 | 2021-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $94.01 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $51.99 | 2023-2024 | Quviviq |
| Corium, LLC | $49.55 | 2024-2025 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $43.87 | 2024 | |
| Collegium Pharmaceutical, INC. | $41.85 | 2025 | Jornay Pm |
| Eisai INC. | $24.81 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.65 | 2024 | Qelbree |
| Noven Therapeutics, LLC | $24.25 | 2023 | Secuado, Xelstrym |
| Acadia Pharmaceuticals INC | $21.32 | 2024 | Nuplazid |
| Noven Pharmaceuticals, INC. | $17.43 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Mcdonough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.